Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127074061 | 12707406 | 1 | I | 20160723 | 20160829 | 20160901 | 20160901 | PER | US-CELGENEUS-USA-2016087680 | CELGENE | 27.76 | YR | M | Y | 0.00000 | 20160901 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127074061 | 12707406 | 1 | PS | THALOMID | THALIDOMIDE | 1 | Oral | U | 20785 | 200 | MG | CAPSULES | QD | ||||||
| 127074061 | 12707406 | 2 | SS | THALOMID | THALIDOMIDE | 1 | Oral | U | 20785 | 200 | MG | CAPSULES | QD | ||||||
| 127074061 | 12707406 | 3 | SS | THALOMID | THALIDOMIDE | 1 | Oral | U | 20785 | 200 | MG | CAPSULES | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127074061 | 12707406 | 1 | Brain neoplasm malignant |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127074061 | 12707406 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127074061 | 12707406 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127074061 | 12707406 | 1 | 201410 | 0 | ||
| 127074061 | 12707406 | 2 | 201604 | 0 | ||
| 127074061 | 12707406 | 3 | 20160513 | 20160716 | 0 |